Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds and methods for activating NAMPT in a subject. The compounds described herein are useful in treating a neurological disorder, disease, or condition. In another aspect, compounds described herein are useful in treating metabolic disorders and diabetes.

Abstract: Provided herein are PLpro inhibitors and methods of treating and/or preventing an infection caused by a coronavirus by administration of one or more of said PLpro inhibitors to a subject in need thereof, as well as pharmaceutical formulations and kits for use in these methods.

Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds that increase the amount of nicotinamide adenine dinucleotide (NAD+) in a subject. By raising the amount of nicotinamide adenine dinucleotide in a subject, diseases associated with reduced levels of nicotinamide adenine dinucleotide can be treated or prevented. In one aspect, raising the amount of NAD+ in a subject can reduce or ameliorate one or more symptoms of Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, multiple sclerosis, amylotrophic lateral sclerosis, AIDS-induced dementia, or epilepsy.